In the States
Select a state to learn more
State Activity
2015 Session: Convene: 1/14/15 and Adjourn: 4/13/15
Maryland House Committee on Health and Government Operations held its hearing on the bill on 4/2/15
3/18/15: Third reading passed (46-0) in Senate
-
Bill Information
Defines an “interchangeable biological product” as a biological product determined to be interchangeable by FDA or a product that has been deemed therapeutically equivalent by FDA.
Directs a pharmacist to inform each consumer of an interchangeable biosimilar and the approximate price difference compared to the biologic, except if:
—prescriber does not prohibit substitution;
—the pharmacy primarily serves institutional recipients; or
—the cost of prescription is reimbursed by a third-party payer, such as an insurer.
Directs the Board to maintain on its website a list of approved interchangeable products.
Permits dispensing of an interchangeable biological product, provided that:
—prescriber does not indicate that substitution is prohibited;
—the consumer is charged less for the biosimilar than the price of the biologic;
—pharmacist notifies the patient in writing;
—pharmacist records the substitution; and
—pharmacist notifies the prescriber within 5 days (under SB 537) or 10 days (under HB 733), electronically if possible (and by other means if not), except when the prescription is a refill that is unchanged from the prior filling.
Establishes that a pharmacist who substitutes a biosimilar is not subject to greater liability than would be incurred in filling the biologic prescription.
Permits the Department (of Health and Mental Hygiene) to disqualify an interchangeable biosimilar from being used in Maryland as a substitute for a biologic, if the Department determines that the product is not interchangeable, or has negative physical or biological effect on the consumer. In making such determination, the Department must generally provide an opportunity for public comment.
-
Archive
BIO International Convention
June 17, 2011
June 27-30, 2011 Walter E. Washington Convention Center Washington, D.C. Read More
BIO International Convention
June 17, 2011
June 27-30, 2011 Walter E. Washington Convention Center Washington, D.C. Read More
Partnering with Global Health Forum
June 17, 2011
June 27, 2011 Walter E. Washington Convention Center Washington, D.C. Read More
BIO Executive Training Programs
June 17, 2011
June 27, 2011 Walter E. Washington Convention Center Washington, D.C. Read More
BIO Executive Training Programs
June 17, 2011
June 27, 2011 Walter E. Washington Convention Center Washington, D.C. Read More
BIO Human Resources Conference
June 17, 2011
June 26-28, 2011 Renaissance Hotel Washington, D.C. Read More
BIO Human Resources Conference
June 17, 2011
June 26-28, 2011 Renaissance Hotel Washington, D.C. Read More
The Interactive Maryland Biosciences Resource Map
June 17, 2011
Governor Martin O’Malley and the Maryland Biotechnology Center unveiled the Maryland BioStat at BIO 2009 International Conference in Atlanta, GA. The Maryland BioStat is an interactive map containing a database of Maryland’s rich bioscience assets – from its companies to academic and federal life sciences research centers, to its research parks, incubators and other critical […]
The Maryland Drug Discovery and Development Network
June 17, 2011
The Maryland Drug Discovery and Development Network (MDDDN) is a new initiative that has been developed by the principal life sciences research institutions of the University System of Maryland (USM), Johns Hopkins University, and selected Community Colleges. Read More
BioMaryland 2020: Strategic Framework and Proposed Policy Actions
June 17, 2011
The nation and the world are going through highly turbulent economic times that expose the interconnected nature of today’s global economy. While the day-to-day ups and downs of the global economy garner newspaper headlines, an intense global competition is underway to attract and develop the innovative, high-growth knowledge industries of the future. Read More
